Gray Elliot, Mitchell Elizabeth, Jindal Sonali, Schedin Pepper, Chang Young Hwan
Department of Biomedical Engineering and Computational Biology Program.
Department of Cell, Developmental and Cancer Biology Oregon Health & Science University.
Proc IEEE Int Symp Biomed Imaging. 2018 Apr;2018:796-799. doi: 10.1109/ISBI.2018.8363692. Epub 2018 May 24.
Ductal carcinoma in situ (DCIS) is breast cancer confined within mammary ducts, surrounded by an intact myoepithelial cell layer that prevents local invasion. A DCIS diagnosis confers increased lifetime risk of developing invasive breast cancer (IBC) and results in surgical excision with radiation, and possibly endocrine- or chemo-therapy. DCIS is known to be over treated, with associated co-morbidities. Biomarkers are needed that delineate patients at low risk of DCIS progression from patients requiring more aggressive treatment. Investigating the role of myoepithelial cell differentiation in barrier function is anticipated to provide insight into DCIS progression and delineate between low and high risk lesions. Here, we develop a high throughput technique to assess loss of myoepithelial differentiation markers. This method facilitates automated analysis of a clinically relevant histopathologic feature, as demonstrated by a high correlation with pathologist annotation (r = 0.959), and further, contributes analytical foundations to a multiplexed immunohistochemistry (IHC) approach.
导管原位癌（DCIS）是局限于乳腺导管内的乳腺癌，被完整的肌上皮细胞层所包围，该细胞层可防止局部浸润。DCIS的诊断会增加患浸润性乳腺癌（IBC）的终生风险，并导致手术切除加放疗，可能还需要内分泌或化疗。已知DCIS存在过度治疗及相关合并症的情况。需要生物标志物来区分低风险DCIS进展患者和需要更积极治疗的患者。研究肌上皮细胞分化在屏障功能中的作用有望深入了解DCIS的进展，并区分低风险和高风险病变。在此，我们开发了一种高通量技术来评估肌上皮分化标志物的缺失。该方法有助于对临床相关组织病理学特征进行自动分析，与病理学家的注释具有高度相关性（r = 0.959），此外，还为多重免疫组织化学（IHC）方法奠定了分析基础。
